LTGO — Latigo Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2056611 ·
Last close
$13.76
Market Cap
$912.28M
52W High
$25.93
52W Low
$10.24
ADV30
276,827
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -22,929,000 | -20,949,000 | 408,456,000 | 401,241,000 | 14,482,000 |
| Jun 2026 | 0 | — | -25,808,000 | -25,797,000 | 64,760,000 | 55,003,000 | 340,840,000 |
| Mar 2026 | 0 | — | -23,436,000 | -22,961,000 | 50,581,000 | 42,177,000 | 303,160,000 |
| Dec 2025 | 0 | — | -38,412,000 | -37,584,000 | 75,516,000 | 69,437,000 | 307,190,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,066,000
Investing CF
$-245,000
Financing CF
$133,382,000
CapEx
$-135,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.01
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-291,889,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-96,329,000
Pretax Income TTM
$-95,545,000
Interest Exp TTM
$251,000
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -110,392,000 | -109,167,000 | 75,516,000 | 307,190,000 | -231,674,000 | -97,557,000 |
| Dec 2024 | 0 | -63,451,000 | -61,183,000 | 22,864,000 | 152,463,000 | -129,599,000 | -50,955,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$64,760,000
Forward EPS
$-2.09
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VSTM | Verastem, Inc. | $933.77M | $7.41 | — |
| AKTS | Aktis Oncology, Inc. | $879.52M | $16.31 | — |
| MLTX | MoonLake Immunotherapeutics | $957.45M | $11.25 | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $857.87M | $10.17 | — |
| SPTX | Seaport Therapeutics, Inc. | $972.65M | $18.17 | — |
News headlines (Yahoo Finance, 1h cache)
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 11:47 · Yahoo
Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
2026-11-05 11:45 · Yahoo
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
2026-11-03 21:05 · Yahoo
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
2026-09-08 18:01 · Yahoo
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-09-03 20:05 · Yahoo
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued
2026-08-10 03:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.